Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 20, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) or persons closely associated with them.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively reports on specific share transactions.
| Transaction Date | Instrument | Price per ADS | Total Volume |
|---|---|---|---|
| October 19, 2017 | GlaxoSmithKline plc ADSs (ISIN: US37733W1053) | $41.1310 | 1,851.735 ADSs |
Note: Total volume is the aggregate of three separate transactions executed on the same date at the same price.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of American Depositary Shares (ADSs) by three executives following the re-investment of dividends paid on October 12, 2017.
Management Commentary and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of specific equity transactions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ADSs via dividend re-investment, not open-market purchases.
- Executives Involved:
- Mr. N. Hirons (SVP, Global Ethics & Compliance): 17.483 ADSs
- Mr. B. McNamara (CEO, Consumer Healthcare): 207.139 ADSs
- Mr. D. E. Troy (SVP & General Counsel): 1,627.113 ADSs
- Market Data: Transactions occurred on the New York Stock Exchange (XNYS) at a uniform price of $41.1310 per ADS.
- Financial Data: This filing does not provide quarterly or annual financial results; investors should refer to the company's Form 20-F or earnings releases for financial metrics.